COVID-19 survival poor for hematopoietic stem cell transplant recipients

Reuters Health - 02/02/2021 - Approximately one in three hematopoietic stem-cell transplant recipients who develop COVID-19 infections die within 30 days of diagnosis, according to a new study that also identifies factors associated with even greater mortality risk. Researchers examined data on 318 hematopoietic stem-cell transplant (HSCT) recipients diagnosed with COVID-19 from March 27, 2020, to August 12, 2020. The primary endpoint was overall survival 30 days after diagnosis, with median follow-up of 21 days for allogenic HSCT recipients and 25 days for autologous HSCT recipients. At 30 days, overall survival was 68% for allogenic HSCT and 67% for autologous HSCT, researchers report in The Lancet Haematology. "The overall survival estimates … at 30-days after COVID infection are quite poor," said lead study author Dr. Akshay Sharma of St. Jude Children's Research Hospital in Memphis, Tennessee. "We did not perform a systematic comparison with other...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 2 February, 202116 February, 2021